Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance

NEW YORK, April 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Inovio Pharmaceuticals, Inc. Analyst Notes 

On March 26, 2014, Inovio Pharmaceuticals, Inc. (Inovio) announced that it has been awarded at the World Vaccine Congress held in Washington, D.C. According to Inovio, the Company has been presented with three industry awards: "Best Therapeutic Vaccine," "Best Licensing Deal," and "Best Early Stage Vaccine Biotech" by the Vaccine Industry Excellence (ViE) Awards. "We greatly appreciate the World Vaccine Congress' recognition of Inovio's leadership and innovation in advancing a vital new generation of immune-system-stimulating therapies and vaccines," said Dr. J. Joseph Kim, President and CEO. The full analyst notes on Inovio Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/INO/report.pdf

--

LifePoint Hospitals Inc. Analyst Notes 

On March 14, 2014, LifePoint Hospitals Inc. (LifePoint) announced that its joint venture with Duke University Health System, Duke LifePoint Healthcare, has partnered with Conemaugh Health System. According to the Company, the board members of Conemaugh Health System signed a letter of intent which states that Duke LifePoint has agreed to invest more than half a billion dollars over the next decade to strengthen and grow the Conemaugh Health system, which includes its three hospitals, outpatient centers, and Conemaugh Physician Group practices. Chairman and CEO William F. Carpenter III commented, "We're honored to be selected as Conemaugh's health care partner. Conemaugh is an excellent health system with an unwavering commitment to its patients, employees and physicians. We look forward to exploring this potential partnership and working with Conemaugh to further strengthen and advance health care throughout this region." The full analyst notes on LifePoint Hospitals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/LPNT/report.pdf

--

Mallinckrodt plc Analyst Notes 

On March 19, 2014, Mallinckrodt plc (Mallinckrodt) announced that it has completed the acquisition of Cadence Pharmaceuticals, Inc. for $1.4 billion. According to the Company, it expects immediate accretion to its fiscal year 2014 adjusted diluted EPS, and significant accretion by fiscal year 2015 adjusted diluted EPS. The Company also stated that its brand roster will now include OFIRMEV (acetaminophen) injection, which will also help expand Mallinckrodt's services in U.S. hospitals. Mallinckrodt President and CEO Mark Trudeau said, "We believe this accelerated integration will provide greater clarity and direction for the employees joining us, and ensure that the merger of OFIRMEV and the transition of the hospital team into Mallinckrodt is smooth and best serves our customers." The full analyst notes on Mallinckrodt plc are available to download free of charge at:

http://www.AnalystsReview.com/04022014/MNK/report.pdf

--

Ligand Pharmaceuticals Incorporated Analyst Notes 

On March 17, 2014, Ligand Pharmaceuticals (Ligand) announced that it has received a $1 million milestone payment following the U.S. Food and Drug Administration's (FDA) recent approval of Merck's NOXAFIL (posaconazole) injection (18 mg/mL), which is used to treat invasive fungal infections. According to the Company, the new NOXAFIL contains a new Captisol-enabled formulation for intravenous (IV) use and will be sold by Merck under a commercial supply agreement. "Ligand's business is thriving with the continued success of our partners with late-stage clinical and regulatory events. This is the second new product expected to be made available in 2014 following the launch of Duavee last month by Pfizer and three additional Ligand-partnered programs are pending approvals in 2014," said John Higgins, President and CEO of Ligand. The full analyst notes on Ligand Pharmaceuticals Incorporated are available to download free of charge at:

http://www.AnalystsReview.com/04022014/LGND/report.pdf

--

Theravance Inc. Analyst Notes 

On March 26, 2014, Theravance Inc. (Theravance) announced that SVP and COO Michael W. Aguiar will be presenting at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 9:20 a.m. EDT. The conference will be held from April 8, 2014 to April 9, 2014 at The Westin New York Grand Central Hotel, New York, NY. The live webcast will be available online via Theravance's website. As stated by the Company, interested parties must visit the site to register, download and install any necessary audio software at least 15 minutes before the scheduled time. The full analyst notes on Theravance Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04022014/THRX/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review